GTS. Earn CME credits at
|
|
- Phoebe Barber
- 6 years ago
- Views:
Transcription
1 Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center Sandra P. D Angelo, MD, Bernard Park, MD, Christopher G. Azzoli, MD, Mark G. Kris, MD, Valerie Rusch, MD, Marc Ladanyi, MD, and Maureen F. Zakowski, MD Objective: The genes KRAS and EGFR have emerged as potential targets for therapy in lung adenocarcinoma; mutations in these genes can be found in almost half of patients. In anticipation of the clinical importance of molecularly defined adenocarcinoma subgroups for the treatment of patients with resected stages I through III lung adenocarcinoma, the Memorial Sloan Kettering Cancer Center (MSKCC) Departments of Surgery and Pathology have collaborated since 2006 to conduct reflex testing of tumor specimens for EGFR and KRAS mutations. Methods: Using established methods, the identification of EGFR exon 19 deletions and exon 21 L858R mutations was performed. In samples lacking these 2 sensitizing EGFR mutations, KRAS analysis was done. Results: We studied a total of 1831 patients who had stage I through IV lung adenocarcinomas and detected 448 KRAS and 364 EGFR mutations. Of these patients, a subset of 855 (78%) patients with stages I through III adenocarcinoma of the lung who underwent curative surgical resection at MSKCC were tested. In patients with early stage disease, 158 EGFR mutations and 207 KRAS mutations were detected. Conclusions: The results of the first 3 years of reflex testing at MSKCC reported here demonstrate the feasibility, clinical utility, and potential of this approach. This information allowed for enrollment of patients into clinical trials to explore mutation-specific, directed therapy and led to retrospective studies related to patient outcome. In addition, it may inform selection of chemotherapy for recurrent disease and may help to distinguish multiple primary tumors from metastatic disease. (J Thorac Cardiovasc Surg 2011;141:476-80) Earn CME credits at Despite successful surgery, half of patients with resected non small-cell lung cancer (NSCLC) recur and die within 5 years. 1 In patients with resected stage II through III NSCLC, 4 months of cisplatin-based chemotherapy improves survival rates by nearly 20% (relative risk reduction), with an absolute risk reduction of 10% to 13%. 2 Pathologic stage is the only prospectively validated clinical factor used to select patients for adjuvant chemotherapy. 3 More effective adjuvant therapies are sorely needed. The most promising molecular markers for the selection of treatment are somatic mutations in lung adenocarcinomas. From Memorial Sloan Kettering Cancer Center, New York, NY. Disclosures: Authors have nothing to disclose with regard to commercial support. Received for publication April 23, 2010; revisions received June 24, 2010; accepted for publication Aug 1, 2010; available ahead of print Oct 8, Address for reprints: Sandra P. D Angelo, MD, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY ( dangelos@mskcc.org) /$0.00 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery doi: /j.jtcvs Epidermal growth factor receptor (EGFR) is a signaling protein attached to the cell membrane. Ligand binding to the extracellular portion of the EGFR protein leads to increases in cellular proliferation, motility, adhesion, invasion, blocking of apoptosis, and resistance to chemotherapy. 4 Erlotinib is an EGFR tyrosine kinase inhibitor currently approved for patients with metastatic NSCLC. Of all clinically relevant EGFR mutations, 90% are either missense mutations in exon 21 or deletions in exon Patients with deletions in exon 19 have better prognoses than patients with missense mutations in exon 21 when treated with erlotinib and gefinitib. 6 EGFR mutations are more common in people who have never smoked, in Asians, and in women with adenocarcinoma. 7 Patients with advanced NSCLC and EGFR exon 19 or 21 mutations have been noted to have high rates of radiologic response to gefitinib. 8 A recent trial in East Asian nonsmokers or former light smokers with stage IV adenocarcinoma evaluated gefitinib against carboplatin and paclitaxel as first-line chemotherapy. In the subgroup of patients with EGFR mutations, patients treated with gefitinib had higher objective responses 71% as opposed to 1% and longer progression-free survival. 9 These trials exemplify the importance of EGFR mutations as predictors of response and clinical benefit from tyrosine kinase inhibitors in patients with stage IV lung adenocarcinoma. 476 The Journal of Thoracic and Cardiovascular Surgery c February 2011
2 General Thoracic Surgery Abbreviations and Acronyms ACCP ¼ American College of Chest Physicians NSCLC ¼ non small-cell lung cancer MSKCC ¼ Memorial Sloan Kettering Cancer Center PCR ¼ polymerase chain reaction KRAS genes encode guanosine triphosphate-binding proteins that regulate cell growth, differentiation, and apoptosis. 10 KRAS mutations occur in 20% to 30% of lung adenocarcinomas. 11 More than 80% occur in exon 2 of KRAS in codon 12, with the remaining mutations occurring in codons 13 and 61. Although detected in some who have never smoked, they are found more often in current and former cigarette smokers and have been associated with poor prognoses in several studies. 12,13 In stage IV patients, KRAS mutations predict lack of response to EGFR tyrosine kinase inhibitors and lower efficacy of chemotherapy when combined with erlotinib. 14 The results of a prospective clinical trial of adjuvant chemotherapy for resected stage IB-II NSCLC did not demonstrate a benefit from adjuvant chemotherapy in the KRAS mutant subgroup (HR, 0.95; 95% CI; P ¼.87). 15 At MSKCC, routine reflex testing for EGFR and KRAS mutations was instituted for all patients with resected lung adenocarcinomas in Justification for this reflex testing is outlined in Table 1. Although it does not guide standard practice, the molecular information has been used to enroll patients in clinical trials of novel adjuvant therapy specifically targeting EGFR and KRAS. 3 Knowing that as much as 50% of patients with resected NSCLC would experience recurrence, we believed that the results of the molecular tests could inform the selection of chemotherapy for recurrent disease. EGFR/KRAS testing has been used to assist in distinguishing multiple primary tumors from metastatic tumors. 16 Resected specimens routinely provide excess tissue for molecular profiling. In contrast, patients with advanced NSCLC are usually diagnosed with a fine needle aspirate, limiting available tissue for analysis. Universal testing of all resected lung adenocarcinomas for EGFR and KRAS mutations has allowed for unique research efforts, including retrospective studies related to outcome and prospective studies of novel agents. Here we report the results of the first 3 years of reflex testing conducted by the pathology department of our institution. MATERIALS AND METHODS We tested all patients who underwent lung resection because of adenocarcinoma. EGFR/KRAS mutations are extremely uncommon in large cell carcinomas, small cell carcinomas, and squamous cell carcinomas. 17 At the time of gross prosection, a slice of tumor was frozen and retained along with a corresponding section for paraffin embedding and hematoxylin and eosin (H&E) staining. Initially, DNA was extracted from frozen tissue. After observing that several cases lacked sufficient tumoral DNA when the frozen tissues were used, we modified the process and instead extracted DNA from formalin-fixed paraffin-embedded tissue to ensure that a sufficient percentage of tumor cells (target >50%) was present in the tissue from which the DNA was prepared. After microscopic examination confirmed the diagnosis of adenocarcinoma, tissue was sent to our CLIA-certified molecular diagnostic laboratory in the Department of Pathology for extraction of DNA and identification of EGFR exon 19 deletions and exon 21 L858R mutations by polymerase chain reaction (PCR) assay. Nonsequencing-based PCR assays are used to detect these mutations. 18 In samples lacking these 2 sensitizing EGFR mutations, KRAS analysis is done by direct sequencing of exon 2 using PCR products. Molecular profiling for EGFR/KRAS has been approved by the New York State Department of Health. A molecular diagnostic report is created and forwarded to the patient s medical record for inspection by the patient s surgeon and medical oncologist (Figure 1). RESULTS Between 2006 and April 2009, tumors of 1831 patients with stage I through IV adenocarcinoma of the lung underwent reflex testing, and 448 KRAS and 364 EGFR mutations were detected. Of those patients, 1097 with stages I through III adenocarcinoma of the lung underwent curative surgical resection at MSKCC. A subset of 855 patients (78%) were tested. In the patients in the early stages, 158 EGFR mutations and 207 KRAS mutations were detected (Table 2). The group included 291 males and 564 females; 594 patients were in stage I; 111 were in stage II; and 147 were in stage III. In 2006, 124 patients underwent mutation testing; 19% had EGFR mutations, and 23% had KRAS mutations (Table 3). In 2007, 324 patients underwent mutation testing; 14% had EGFR mutations, and 20% had KRAS mutations. In 2008, 293 patients underwent mutation testing; 25% had EGFR mutations, and 30% had KRAS mutations. As of April 2009, 114 patients have undergone mutation testing; 25% haveegfr mutations and 30% have KRAS mutations (Table 3). Already, 15% of these patients have experienced recurrences, and genetic information from their resected specimens has been used to select therapy. DISCUSSION Reflex testing of adenocarcinomas for EGFR and KRAS mutations at MSKCC over the past 3 years reveals some interesting observations. Nearly 78% of patients with earlystage disease have undergone mutation testing. The majority of patients with resected adenocarcinoma are females, at a nearly 2 to 1 ratio. It is unclear whether this trend is the result of demographics unique to our patient population, is related to the preponderance of adenocarcinoma in females versus males, or is related to differing smoking habits in females and males. This sex distribution is not seen in our advanced-stage patients; in a database of 1081 cases of stage IV adenocarcinomas, 59% were women. It is interesting that in a recent report concerning a large group of patients that was screened for lung cancer, it was found that the prevalence of screen-detected early The Journal of Thoracic and Cardiovascular Surgery c Volume 141, Number 2 477
3 TABLE 1. Clinical utility of reflex testing in early-stage (I through III) adenocarcinoma It informs selection of chemotherapy for recurrent disease. It may help to distinguish multiple primary tumors from metastatic disease. It allows for enrollment of patients into clinical trials to explore mutationspecific therapy. It encourages additional research efforts, including retrospective studies related to patient outcome. TABLE 2. Patient characteristics Male Female Stage I Stage II Stage III Total tested cancers was higher in women than in men, even though women had less exposure to smoking. 19 Most resections for NSCLC at MSKCC occur at stage I, which is a stage of the disease for which no routine adjuvant therapy exists. 20 They are performed in a population of patients for whom opportunities to participate in clinical trial are especially important. Counted together, EGFR and KRAS mutation testing identifies a driver mutation in nearly half of the cases of resected adenocarcinomas at our institution. To date, 15% of patients who have undergone reflex testing of resected adenocarcinoma have experienced recurrence of disease. Given the short median follow-up, it is no surprise that the majority of patients with early recurrence were found to have lymph-node metastases (ie, stage II through III) at the time of surgery. In these patients, the molecular characteristics of their tumors were immediately available to inform the selection of therapy for recurrent, stage IV disease. An alternative approach would be to test for these mutations at the time of recurrence. FIGURE 1. Reflex testing flowchart Patients at MSKCC receive postoperative, cisplatinbased chemotherapy according to established standards of care. 21 Pathologic stage is the most important factor in selecting patients for adjuvant therapy. Previous data have supported the role of adjuvant cisplatin-based chemotherapy in patients with stage II through III NSCLC. The higher the stage, the more benefit is derived from adjuvant chemotherapy. 22 Other than stage, no clinical factors are predictive of the benefits of treatment. Historically, criteria developed by Martini and Melamed and the American College of Chest Physicians (ACCP) have been used to distinguish multiple primary lung tumors from metastatic lesions. 23,24 These criteria often provide conflicting results. A recent report interpreted 7 patients tumors using the Martini-Melamed criteria, the ACCP criteria, and comprehensive histologic subtyping. When the Martini-Melamed criteria were applied, 6 of 7 patients were determined to have had multiple primary lung tumors. According to the ACCP criteria, 3 patients had multiple primaries, and 3 had metastases; the seventh patient s case was indeterminate. However, based on comprehensive histologic subtyping, all of the patients had multiple primary lung tumors. Mutational testing also suggested that the tumors were multiple primary lung adenocarcinomas. This case series demonstrates that molecular profiling can assist in clarifying clinical issues and in resolving conflicts among existing clinical criteria. 16 Reflex testing has allowed for retrospective studies of the impact of gefitinib and erlotinib as adjuvant therapy for patients with stage I through III adenocarcinomas of the lung that harbor an EGFR mutation. We have reported improved disease-free survival rates in patients with completely resected stage I through III adenocarcinomas with EGFR mutations who were treated with perioperative gefitinib or erlotinib compared to individuals who did not receive treatment with EGFR TKI. 25 We evaluated 150 patients (112 women, 38 men) who had completely resected stage I through III lung adenocarcinoma and whose resection specimens contained EGFR-activating mutations in exon 19 or 21. Of those patients, 42 (28%) received cytotoxic chemotherapy, and 48 (32%) received either erlotinib (n ¼ 26) or gefitinib (n ¼ 22) postoperatively. The median time on a TKI was 16 months. The median disease-free survival (DFS) was 43 months in the patients who received TKI as 478 The Journal of Thoracic and Cardiovascular Surgery c February 2011
4 General Thoracic Surgery TABLE 3. Results through April Resected adenocarcinomas Total tested Percent tested EGFR mutant KRAS mutant EGFR/KRAS wild type Recurred 30 (24%) 61 (19%) 38 (13%) 3 (3%) Stage I 13 (17%) 35 (15%) 19 (9%) 1 (1%) Stage II 6 (38%) 11 (28%) 7 (17%) 1 (1%) Stage III 11 (38%) 15 (30%) 12 (25%) 2 (20%) opposed to 31 months in those who did not. After controlling for stage, we found that individuals who received adjuvant gefitinib or erlotinib had a better DFS (HR, 0.56; 95% CI, ; P ¼.157) than the non-tki group. Currently a multicenter phase-2 trial is evaluating the role of adjuvant erlotinib in patients with resected adenocarcinomas. This combined experience may serve as the basis for recommending perioperative treatment with erlotinib, based on the reflex identification of an EGFR mutation in all patients following resection. Reflex testing for EGFR and KRAS mutation at our institution has allowed for studies of the prognostic significance of these molecular markers. We evaluated 1000 patients (618 women) who had stage I (732), stage II (121), or stage III (147) lung adenocarcinomas. Median follow-up was 16 months. After adjustment for stage, there was a trend toward better survival rates in EGFR mutation-positive patients (n ¼ 145) compared to wild type (n ¼ 588) (HR, 0.76; 95% CI, ; P ¼.3). There was a trend toward worse survival rates in patients with KRAS mutation (n ¼ 267) compared to wild type (HR, 1.20; 95% CI, ; P ¼.4). The 3-year survival proportions for each group were: EGFR mutation 80% (95% CI, ); KRAS mutation 73% (95% CI, ); wild type 73% (95% CI, ). 26 Reflex testing has allowed us to select patients for research studies of mutation-specific adjuvant therapy. Currently, we have enrolled 23 patients in a trial of GI-4000 (GlobeImmune, Inc., Louisville, Colo); recombinant, heat-inactivated yeast (Saccharomyces cerevisiae) engineered to express 1 of 3 mutated KRAS oncoproteins (G12C, G12V, and G12D, representing 85% of the specific KRAS mutations detected in outpatients). 24,27 Patients with KRAS mutations are immunized with a vaccine, and immune response is recorded. As mentioned earlier, patients with EGFR exon 19 or exon 21 mutations are offered the opportunity to enroll in a phase II trial of erlotinib as an adjuvant therapy. To date, 17 patients have been enrolled in this trial. Mutations in EGFR and KRAS are found in one third of lung adenocarcinomas. We have demonstrated that these molecular lesions can be readily identified in resected specimens by reflex testing. As we have recently seen with the identification of the EML4-ALK fusion gene, 28 new genetic lesions with therapeutic implications will emerge and can be readily incorporated into the reflex testing process. Our experience over the past 3 years has demonstrated that reflex testing is feasible. The data obtained through this mechanism provide patients and scientists opportunities for research, and they can also aid in clinical decision making. References 1. Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006;52: Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350: Azzoli CG, Park BJ, Pao W, Zakowski M, Kris MG. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol. 2008;3: Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19: Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn. 2008;10: Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(Pt 1): Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350: Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: Rowinsky EK, Jiroutek M, Bonomi P, Johnson D, Baker SD. Paclitaxel steadystate plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Clin Cancer Res. 1999;5: Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol. 1999;17: Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, et al. Cigarette smoking is strongly associated with mutation of The Journal of Thoracic and Cardiovascular Surgery c Volume 141, Number 2 479
5 the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92: Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92: Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352: Girard N, Deshpande C, Azzoli CG, Rusch V, Travis W, Ladanyi M, et al. Use of EGFR/KRAS mutation yesting to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest. 2010;137: Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21(Suppl 2):S Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7: Henschke CI, Yip R, Miettinen OS. Women s susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA. 2006;296: Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update J Clin Oncol. 2004;22: Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25: Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26: Shen KR, Meyers BF, Larner JM, Jones DR. Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):290S-305S. 24. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70: Janjigian YY, Park BJ, Kris MG, Miller VA, Riely GJ, Zheng J, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations. J Clin Oncol. 2009;27(suppl): D Angelo SP, Janjigian YY, Kris MG, Pao W, Riely GJ, Marks J, et al. Impact of EGFR and KRAS mutations on survival in 1,000 patients with resected lung adenocarcinoma. J Clin Oncol. 2010;28(Suppl): Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, Rodell TC, et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 2004;64: Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448: The Journal of Thoracic and Cardiovascular Surgery c February 2011
Adenocarcinoma of the lung is the leading cause of cancerrelated
ORIGINAL ARTICLE Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma Jenifer L. Marks, MD,* Stephen Broderick, MD, Qin Zhou, MA, Dhananjay Chitale, MD, Allan
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationThe most effective treatment for lung adenocarcinoma is
ORIGINAL ARTICLE Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y. Janjigian, MD,* Bernard J. Park,
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationTest Category: Prognostic and Predictive. Clinical Scenario
Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy Test Category: Prognostic
More informationFrequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung
HeSMO 6(2) 2015 19 23 DOI: 10.1515/fco-2015-0009 Forum of Clinical Oncology Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung Hanan Ezzat Shafik 1 *,
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationIndividualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers
Review Individualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers Norihiko Ikeda, MD, Seisuke Nagase, MD, and Tatsuo Ohira, MD Several prospective randomized trials
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationThe discovery of targetable driver mutations in a subset of
Original Article Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers Anya M. Litvak, MD,* Paul K. Paik, MD,* Kaitlin M. Woo, MS, Camelia S. Sima, MD, Matthew D. Hellmann, MD,*
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationAccepted Manuscript. Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD
Accepted Manuscript Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD PII: S0022-5223(18)31821-X DOI: 10.1016/j.jtcvs.2018.06.069 Reference: YMTC 13198 To appear in: The
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationMutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department
More informationExon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Case Report Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report Yu-Ting Wang, Wei-Wei Ning, Jing Li, Jian-n Huang Department of Respiratory Medicine, the First ffiliated
More informationLung cancer remains the leading cause of cancer-related
Original Article EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma Kosuke Tanaka, MD,* Toyoaki Hida, MD, PhD,* Yuko Oya, MD,* Tomoyo Oguri, MD,
More informationSUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
More informationand management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center
The new role of cytology in the diagnosis and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center Outline Role of cytology in the diagnosis of lung cancer Non-small
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationEGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE EGFR s in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China Can Pi 1,2*, Chong-Rui Xu 2*, Ming-feng Zhang
More informationImproving outcomes for NSCLC patients with brain metastases
Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationPrognosis of recurrent non small cell lung cancer following complete resection
1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI
More informationAdjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?
Editorial Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough? Giandomenico Roviello 1, Marco Imperatori 1, Michele Aieta 1, Francesco Sollitto 2, Matteo Landriscina
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationA nonresponding small cell lung cancer combined with adenocarcinoma
Case Report A nonresponding small cell lung cancer combined with adenocarcinoma Hongyang Lu 1,2, Shifeng Yang 3 1 Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung
More informationPrognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer
Ann Thorac Cardiovasc Surg 2011; 17: 58 62 Case Report Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Motoki Yano, MD, Hidefumi Sasaki, MD, Satoru Moriyama, MD, Osamu Kawano MD, Yu
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationThere has been a growing interest in lung cancer in neversmokers,
ORIGINAL ARTICLE,, and Time of Diagnosis Are Important Factors for Prognosis Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan Tomoya Kawaguchi, MD,* Minoru Takada, MD,*
More informationORIGINAL ARTICLE. Oncology and Translational Medicine DOI /s Abstract
Oncology and Translational Medicine DOI 10.1007/s10330-018-0281-1 August 2018, Vol. 4, No. 4, P158 P162 ORIGINAL ARTICLE Treatment and survival status of patients with EGFR mutation-positive stage IV lung
More informationAdvancing Health Equity in Lung Cancer Outcomes
Advancing Health Equity in Lung Cancer Outcomes Edwin J Jackson Jr. DO Pulmonary and Critical Care Medicine Disclosures Funding: American Thoracic Society 2 1 Lecture Outline Cancer Disparities Smoking
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationAnalysis of Circulating Tumor DNA: the Next Paradigm Shift in Detection and Treatment of Lung Cancer
Accepted Manuscript Analysis of Circulating Tumor DNA: the Next Paradigm Shift in Detection and Treatment of Lung Cancer David S. Schrump, MD, MBA, Julie A. Hong, MS PII: S0022-5223(18)30295-2 DOI: 10.1016/j.jtcvs.2018.01.060
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationANTICANCER RESEARCH 26: (2006)
Diffuse Micronodular Pulmonary Metastasis of Lung Adenocarcinoma Predicts Gefitinib Response in Association with Epidermal Growth Factor Receptor Mutations MAKOTO KOBAYASHI 1, TAMOTSU TAKEUCHI 2, KENTARO
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationAdjuvant Therapies for Lung Cancers: New Directions
Adjuvant Therapies for Lung Cancers: New Directions Mark G Kris, MD Member and Attending Physician William and Joy Ruane Chair in Thoracic Oncology Memorial Sloan-Kettering Professor of Medicine, Weill
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationKRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Open access, freely available online KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib PLoS MEDICINE William Pao 1,2*, Theresa Y. Wang 1, Gregory J. Riely 2, Vincent
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationClinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases
Original Article Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases Yuan-Yuan Lei 1,2, Jin-Ji Yang 2, Wen-Zhao Zhong 2, Hua-Jun Chen
More informationMolecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationAnalysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma Hong
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationPersonalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationFollow this and additional works at:
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2015 Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationRecent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection
ASIP 2009 USCAP Companion Meeting Molecular Pathology for the Practicing Pathologist Recent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationThe ABCs of BAC: Bronchioloalveolar Carcinoma
The ABCs of BAC: Bronchioloalveolar Carcinoma Howard (Jack) West, MD Medical Oncologist Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA March, 2009 President & CEO GRACE
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationYan Zhang 1*, Zheng Wang 2*, Xuezhi Hao 1, Xingsheng Hu 1, Hongyu Wang 1, Yan Wang 1, Jianming Ying 3. Original Article. Abstract
Original Article Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations Yan Zhang
More informationONCOLOGY LETTERS 8: , 2014
ONCOLOGY LETTERS 8: 813-818, 2014 Investigation of the epidermal growth factor receptor mutation rate in non small cell lung cancer patients and the analysis of associated risk factors using logistic regression
More informationMolecular Diagnosis of Lung Cancer
Molecular Diagnosis of Lung Cancer Lucian R. Chirieac, M.D. Assistant Professor of Pathology Harvard Medical School Staff Pathologist, Department of Pathology Brigham and Women's Hospital 75 Francis Street
More informationLara Kujtan, MD; Abdulraheem Qasem, MD
The Treatment of Lung Cancer Between 2013-2014 at Truman Medical Center: A Retrospective Review in Fulfillment of the Requirements of Standard 4.6 (Monitoring Compliance with Evidence- Based Guidelines)
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationEpidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
ORIGINAL ARTICLE Korean J Intern Med 218;33:168-175 https://doi.org/1.394/kjim.215.158 Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
More informationThe 5-year survival in patients with resected NSCLC ranges
SHIRISH M. GADGEEL Role of Chemotherapy and Targeted Therapy in Early-Stage Non Small Cell Lung Cancer Shirish M. Gadgeel, MD OVERVIEW On the basis of several randomized trials and meta-analyses, adjuvant
More informationPIK3CA mutations are found in approximately 7% of
Original Article Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas Juliana Eng, MD,*
More informationTHE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS
THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS PULMONARY PATHOLOGY SOCIETY USCAP, BALTIMORE, March 2, 2013 William D. Travis, M.D. Dept of Pathology, Memorial Sloan-Kettering Cancer
More informationApplying Genomics to Cancer 21 st September The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience
Applying Genomics to Cancer 21 st September 2015 The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience Aled Daniels R Butler, R Attanoos, H Davies University Hospital of Wales
More informationA case of different EGFR mutations in surgically resected synchronous triple lung cancer
Case Report A case of different EGFR mutations in surgically resected synchronous triple lung cancer Naoki Haratake 1, Mitsuhiro Takenoyama 1, Makoto Edagawa 1, Shinichiro Shimamatsu 1, Ryo Toyozawa 1,
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationLung cancer is the leading cause of cancer-related
Original Articles Correlation of Mutation Status With Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationAuthor's response to reviews
Author's response to reviews Title: Evaluation of Safety and Efficacy of Gefitinib ('Iressa', ZD1839) as Monotherapy in a series of Chinese Patients with Advanced Non-small-cell Lung Cancer: Experience
More informationREVIEWS. Personalized medicine in lung cancer: what we need to know. Tony S. K. Mok
Personalized medicine in lung cancer: what we need to know Tony S. K. Mok Abstract Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationResearch Article Mutated KRAS is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
Lung Cancer International Volume 2012, Article ID 587424, 6 pages doi:10.1155/2012/587424 Research Article Mutated KRAS is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease
More information